NCT05152147Phase 3Active not recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-07-15Actual

Enrollment · participants920Actual

Source updated2026-09-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-24 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~30 Sep 2026~~

+ After

15 Jul 2026

Check registry source

Posted 2026-09-01 · 1 field changed

Primary completion date changed

− Before

~~31 Jul 2026~~

+ After

30 Sep 2026

Check registry source

Posted 2025-12-15 · 1 field changed

Primary completion date changed

− Before

~~1 Dec 2025~~

+ After

31 Jul 2026

Check registry source

Posted 2025-10-22 · 1 field changed

Primary completion date changed

− Before

~~15 Oct 2025~~

+ After

1 Dec 2025

Check registry source

Study details

Conditions studied

Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma

Treatments or interventions studied

ZanidatamabDrugAlso known as ZW25, JZP598, ZIIHERA®
TislelizumabDrug
TrastuzumabDrugAlso known as Herceptin®
CapecitabineDrug
OxaliplatinDrug
CisplatinDrug
5-FluorouracilDrug

Primary outcomes · main study measures

Read the study measures

measure: Progression-free survival (PFS) by BICR; description: The time from randomization to the date of documented disease progression (per Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1) as assessed by blinded independent central review (BICR) or death from any cause; timeFrame: Up to 2.5 years; measure: Overall survival; description: The time from randomization to death due to any cause; timeFrame: Up to 3.5 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history